Search results for "Diagnosis treatment"

Diagnosis, treatment and long-term outcomes of autoimmune pancreatitis in Spain based on the International Consensus Diagnostic Criteria: A multi-cen…

2015

Abstract Objectives Autoimmune pancreatitis (AIP) is a form of chronic pancreatitis that has been reported worldwide for the last two decades. The aim of this study is to analyse the clinical profile of patients from Spain with AIP, as well as treatments, relapses and long-term outcomes. Methods Data from 59 patients with suspected AIP that had been diagnosed in 15 institutions are retrospectively analysed. Subjects are classified according to the International Consensus Diagnostic Criteria (ICDC). Patients with type 1 AIP (AIP1) and type 2 AIP (AIP2) are compared. Kaplan–Meier methodology is used to estimate the overall survival without relapses. Results Fifty-two patients met ICDC, 45 pat…

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2014

E. Van Cutsem1, A. Cervantes2, B. Nordlinger3 & D. Arnold4, on behalf of the ESMO Guidelines Working Group* Digestive Oncology, University Hospitals Leuven, Leuven, Belgium; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain; Department of General Surgery and Surgical Oncology, Hopital Ambroise Pare, Assistance Publique – Hopitaux de Paris, Paris, France; Klinik fur Tumorbiologie, Freiburg, Germany

Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2013

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer

2021

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of localised colon cancer was published in 2020. It was decided by both the ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special virtual guidelines meeting in March 2021 to adapt the ESMO 2020 guidelines to take into account the ethnic differences associated with the treatment of localised colon cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with localised colon cancer representing the oncological societies of Japan (JSMO), China (CSCO), India (…

Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

2019

Knowledge of genetic susceptibility to gastrointestinal cancers is constantly evolving with identification of new genes. Similarly, a better understanding of the genotype/phenotype relationship in patients with Lynch syndrome (LS) or familial adenomatous polyposis (FAP) is leading to more individualised surveillance recommendations. In addition, molecular profiling of patients with cancer has been shown to guide targeted therapies, such as immunotherapy. Specialists involved in the care of patients with gastrointestinal cancer should be familiar with the main hereditary cancer syndromes and refer patients to specialised cancer genetic units for adequate genetic counselling and to address sp…

Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010

Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up M. Stahl, W. Budach, H.-J. Meyer & A. Cervantes On behalf of the ESMO Guidelines Working Group* Department of Medical Oncology and Centre of Palliative Care, Kliniken Essen-Mitte, Essen; Department of Radiation Oncology, University of Dusseldorf, Dusseldorf; Department of Surgery, Stadt Klinikum Solingen, Germany; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A. Okines, M. Verheij, W. Allum, D. Cunningham & A. Cervantes On behalf of the ESMO Guidelines Working Group* GI Clinical Trials Unit, Royal Marsden Hospital, Sutton, UK; Department of Radiation Oncology and Division of Cellular Biochemistry, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Surgery, Royal Marsden Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton, UK; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain

Diagnosis, treatment, and analysis of long-term outcomes in idiopathic normal-pressure hydrocephalus

2007

To the Editor:We read with interest the article by McGirt et al. (9) entitled“Diagnosis, Treatment, and Analysis of Long-term Outcomes inIdiopathic Normal Pressure Hydrocephalus.” The authors con-clude that gait impairment is the primary symptom that inde-pendently predicted improvement after shunting. The studyincluded 132 patients, 129 (98%) of whom had gait impairmentas a feature. We would like to comment on this particular selec-tion criterion, as well as improvements in the Mini Mental StateExamination (MMSE) as the sole measure of postoperative cog-nitive improvement.One of the inclusion criteria for this study was presentationwith two or more features of the classic triad. Thus, the …